Identification of lymphoma predictors in patients with primary Sjögren’s syndrome: A systematic literature review and meta-analysis

Rheumatology International

Volumn 35, Issue 1, 2015, Pages 17-26

  Nishishinya, Maria B ^a   Pereda, Claudia A ^b   Muñoz Fernández, Santiago ^c   Pego Reigosa, José M ^d,e   Rúa Figueroa, Iñigo ^f   Andreu, José Luis ^g   Fernández Castro, Mónica ^g   Rosas, José ^h   Santamaría, Estibaliz Loza ⁱ  

^a Instituto Traumatológico Quirón Salud   (Spain)

^b Mediterranea Medica Clinic   (Spain)

^c HOSPITAL UNIVERSITARIO INFANTA SOFÍA   (Spain)

^d UNIVERSITY HOSPITAL COMPLEX OF VIGO   (Spain)

^e Instituto de Investigación Biomédica de Vigo   (Spain)

^f HOSPITAL UNIVERSITARIO DE GRAN CANARIA DR NEGRÍN   (Spain)

^g HOSPITAL UNIVERSITARIO PUERTA DE HIERRO   (Spain)

^h HOSPITAL MARINA BAIXA   (Spain)

ⁱ Institute for Health   (Spain)

Author keywords

Clinical markers; Immunological markers; Lymphoma; Sj gren syndrome

Indexed keywords

COMPLEMENT COMPONENT C3; COMPLEMENT COMPONENT C4; CRYOGLOBULIN; RHEUMATOID FACTOR;

ANEMIA; ARTHRALGIA; CANCER RISK; CD4+ T LYMPHOCYTE; COMPLEMENT BLOOD LEVEL; DISEASE ASSOCIATION; GERMINAL CENTER; HUMAN; HYPERGAMMAGLOBULINEMIA; LYMPHADENOPATHY; LYMPHOCYTOPENIA; LYMPHOMA; LYMPHOPROLIFERATIVE DISEASE; NEUTROPENIA; OVERALL SURVIVAL; PAROTID ENLARGEMENT; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; PURPURA; REVIEW; RISK ASSESSMENT; SENSORIMOTOR NEUROPATHY; SJOEGREN SYNDROME; SPLENOMEGALY; SYSTEMATIC REVIEW; COMPLICATION; FEMALE; MALE; META ANALYSIS; PROGNOSIS; RISK FACTOR;

FEMALE; HUMANS; LYMPHOMA; MALE; PROGNOSIS; RISK FACTORS; SJOGREN'S SYNDROME;

EID: 84926640377     PISSN: 01728172     EISSN: 1437160X     Source Type: Journal    
DOI: 10.1007/s00296-014-3051-x     Document Type: Review

References (49)

1. Jordan RC, Speight PM (1996) Lymphoma in Sjogren's syndrome. From histopathology to molecular pathology. Oral Surg Oral Med O 81(3):308-320
2. Kassan SS, Thomas TL, Moutsopoulos HM, Hoover R, Kimberly RP, Budman DR et al (1978) Increased risk of lymphoma in sicca syndrome. Ann Intern Med 89(6):888-892
3. Pariente D, Anaya JM, Combe B, Jorgensen C, Emberger JM, Rossi JF et al (1992) Non-Hodgkin's lymphoma associated with primary Sjogren's syndrome. Eur J Med 1:337-342
4. Ioannidis JPA, Vassiliou VA, Moutsopoulos HM (2002) Longterm risk of mortality and lymphoproliferative disease and predictive classification of primary Sjogren's syndrome. Arthritis Rheum 46:741-747
5. Smedby KE, Baecklund E, Askling J (2006) Malignant lymphomas in autoimmunity and inflammation: a review of risks, risk factors, and lymphoma characteristics. Cancer Epidemiol Biomarkers Prev 15:2069-2077
6. Smedby KE, Hjalgrim H, Askling J, Chang ET, Gregersen H, Porwit-MacDonald A et al (2006) Autoimmune and chronic inflammatory disorders and risk of non-Hodgkin lymphoma by subtype. J Natl Cancer Inst 98:51-60
7. Zintzaras E, Voulgarelis M, Moutsopoulos HM (2005) The risk of lymphoma development in autoimmune diseases: a meta-analysis. Arch Intern Med 165:2337-2344
8. Voulgarelis M, Skopouli FN (2007) Clinical, immunologic, and molecular factors predicting lymphoma development in Sjogren's syndrome patients. Clin Rev Allergy Immunol 32:265-274
9. Anaya JM, McGuff HS, Banks PM, Talal N (1996) Clinicopathological factors relating malignant lymphoma with Sjogren's syndrome. Semin Arthritis Rheum 25:337-346
10. Biasi D, Mocella S, Caramaschi P et al (1996) Utility and safety of parotid gland biopsy in Sjogren's syndrome. Acta Otolaryngol 116:896-899
11. Oxford Centre for Evidence-Based Medicine (2011) OCEBM Levels of Evidence Working Group*. "The Oxford 2011 Levels of Evidence". http://www.cebm.net/index.aspx?o=5653
12. Kassan SS, Thomas TL, Moutsopoulos HM, Hoover R, Kimberly RP, Budman DR et al (1978) Increased risk of lymphoma in sicca syndrome. Ann Intern Med 89:888-892
13. Baimpa E, Dahabreh IJ, Voulgarelis M, Moutsopoulos HM (2009) Hematologic manifestations and predictors of lymphoma development in primary Sjogren syndrome: clinical and pathophysiologic aspects. Medicine (Baltimore) 88:284-293
14. Brito-Zeron P, Ramos-Casals M, Bove A, Sentis J, Font J (2007) Predicting adverse outcomes in primary Sjogren's syndrome: identification of prognostic factors. Rheumatology 46:1359-1362
15. Davidson BKS, Kelly CA, Griffiths ID (1999) Primary Sjogren's syndrome in the North East of England: a long-term follow-up study. Rheumatology 38:245-253
16. Ioannidis JP, Vassiliou VA, Moutsopoulos HM (2002) Long-term risk of mortality and lymphoproliferative disease and predictive classification of primary Sjogren's syndrome. Arthritis Rheum 46:741-747
17. Kauppi M, Pukkala E, Isomaki H (1997) Elevated incidence of hematologic malignancies in patients with Sjogren's syndrome compared with patients with rheumatoid arthritis (Finland). Cancer Cause Control 8:201-204
18. Lazarus MN, Robinson D, Mak V, Moller H, Isenberg DA (2006) Incidence of cancer in a cohort of patients with primary Sjogren's syndrome. Rheumatology 45:1012-1015
19. Martel C, Gondran G, Launay D, Lalloué F, Palat S, Lambert M et al (2011) Active immunological profile is associated with systemic Sjogren's syndrome. J Clin Immunol 31:1-8
20. Pertovaara M, Pukkala E, Laippala P, Miettinen A, Pasternack A (2001) A longitudinal cohort study of Finnish patients with primary Sjogren's syndrome: clinical, immunological, and epidemiological aspects. Ann Rheum Dis 60:467-472
21. Skopouli FN, Dafni U, Ioannidis JPA, Moutsopoulos HM (2000) Clinical evolution, and morbidity and mortality of primary Sjogren's syndrome. Semin Arthritis Rheum 29:296-304
22. Sutcliffe N, Inanc M, Speight P, Isenberg D (1998) Predictors of lymphoma development in primary Sjogren's syndrome. Semin Arthritis Rheum 28:80-87
23. Theander E, Henriksson G, Ljungberg O, Mandl T, Manthorpe R, Jacobsson LT (2006) Lymphoma and other malignancies in primary Sjogren's syndrome: a cohort study on cancer incidence and lymphoma predictors. Ann Rheum Dis 65:796-803
24. Valesini G, Priori R, Bavoillot D, Osborn J, Danieli G, Del Papa N et al (1997) Differential risk of non-Hodgkin's lymphoma in Italian patients with primary Sjogren's syndrome. J Rheumatol 24:2376-2380
25. Zhang W, Feng S, Yan S, Zhao Y, Li M, Sun J et al (2010) Incidence of malignancy in primary Sjogren's syndrome in a Chinese cohort. Rheumatology 49:571-577
26. Smedby KE, Vajdic CM, Falster M et al (2008) Autoimmune disorders and risk of non-Hodgkin lymphoma subtypes: a pooled analysis within the Inter Lymph Consortium. Blood 111:4029-4038
27. Solans-Laque R, Lopez-Hernandez A, Angel Bosch-Gil J, Palacios A, Campillo M, Vilardell-Tarres M (2011) Risk, predictors, and clinical characteristics of lymphoma development in primary Sjogren's syndrome. Semin Arthritis Rheum 41:415-423
28. Vitali C, Bombardieri S, Moutsopoulos HM, Balestrieri G, Bencivelli W, Bernstein RM et al (1993) Preliminary criteria for the classification of Sjögren's syndrome. Results of a prospective concerted action supported by the European Community. Arthritis Rheum 36:340-347
29. Vitali C, Bombardieri S, Jonsson R, Motsopulos HM, Alexander EL, Carsons SE et al (2002) Classification criteria for Sjögren's syndrome: a revised version of the European criteria proposed by the American-European Consensus Group. Ann Rheum Dis 61:554-558
30. Fox RIRC, Curd JG, Kozin F, Howell FV (1986) Sjögren's syndrome. Proposed criteria for classification. Arthritis Rheum 29:577-585
31. Manthorpe R, Oxholm P, Prause JU, Schiødt M (1986) The copenhagen criteria for Sjögren's syndrome. Scand J Rheumatol Suppl 61:19-21
32. Shiboski SC, Shiboski CH, Criswell LA, Baer AN, Challacombe S, Lanfranchi H et al (2012) American College of Rheumatology classification criteria for Sjögren's syndrome: a data-driven expert consensus approach in the Sjögren's International Collaborative Clinical Alliance Cohort. Arthritis Care Res 64:475-487
33. Liang Y, Yang Z, Qin B, Zhong R (2013) Primary Sjögreńs syndrome and malignancy risk: a systematic review and meta-analysis. Ann Rheum Dis. doi:10.1136/annrheumdis-2013-203305
34. Johnsen SJBJG, Goransson LG, Smastuen MC, Johannesen TB, Haldorsen K et al (2013) Risk of non-Hodgkińs lymphoma in primary Sjögreńs syndrome: a population-based study. Arthritis Care Res 65:816-821
35. Risselada AP, Kruize AA, Bijlsma JW (2013) Clinical features distinguishing lymphoma development in primary Sjögreńs syndome-a retrospective cohort study. Semin Arthritis Rheum 43:171-177. doi:10.1016/j.semarthrit.2013.03.001
36. Quartuccio L, Isola M, Baldini C, Priori R, Bartoloni Bocci E, Carubbi F et al (2013) Biomarkers of Lymphoma in Sjögreńs syndrome and evaluation of the lymphoma risk in prelymphomatous conditions: results of a multicenter study. J Autoimmun. doi:10.1016/j.jaut.2013.10.002
37. Theander E, Manthorpe R, Jacobsson LTH (2004) Mortality and causes of death in primary Sjögren syndrome. Arthritis Rheum 50:1262-1269
38. Theander E, Henriksson G, Ljungberg O, Mandl T, Manthorpe R, Jacobsson LTH (2006) Lymphoma and other malignancies in primary Sjogren's syndrome: a cohort study on cancer incidence and lymphoma predictors. Ann Rheum Dis 65:796-803
39. Dong LCY, Masaki Y, Okazaki T, Umehara H (2013) Possible mechanisms of lymphoma development in Sjögren's syndrome. Curr Immunol Rev 9:13-22
40. Routsias JGGJ, Georgios Charalampakis DMD, Tzima S, Papageorgiou A, Voulgarelis M (2013) Malignant lymphoma in primary Sjögren syndrome: an update on the pathogenesis and treatment. Semin Arthritis Rheum 43:178-186
41. Brito-Zeron P, Ramos-Casals M (2008) Prognosis of patients with primary Sjogren's syndrome. Med Clin (Barc) 130:109-115
42. Theander E, Vasaitis L, Baecklund E, Nordmark G, Warfvinge G, Liedholm R et al (2011) Lymphoid organisation in labial salivary gland biopsies is a possible predictor for the development of malignant lymphoma in primary Sjogren's syndrome. Ann Rheum Dis 70:1363-1368
43. Nezos A, Papageorgiou A, Fragoulis G, Loakeimidis D, Koutsilieris M, Tzioufas AG et al (2013) B-cell activating factor genetic variants in lymphomagenesis associated with primary Sjögreńs syndrome. J Autoimmun. doi:10.1016/j.jaut.2013.04.005
44. Tobón GJSA, Gottenberg J-E, Quartuccio L, Fabris M, Seror R et al (2013) Role of Fms-like tyrosine kinase 3 ligand as a potential biologic marker of lymphoma in primary Sjögreńs syndrome. Arthritis Rheum 65:3218
45. Biasi D, Caramaschi P, Ambrosetti A et al (2001) Mucosa-associated lymphoid tissue lymphoma of the salivary glands occurring in patients affected by Sjogren's syndrome: report of 6 cases. Acta Haematol 105:83-88
46. Zufferey P, Meyer OC, Grossin M, Kahn MF (1995) Primary Sjogren's syndrome (SS) and malignant lymphoma. A retrospective cohort study of 55 patients with SS. Scand J Rheumatol 24:342-345
47. Ismail F, Mahmoud A, Abdelhaleem H, Mamdoh A, Geneidy M, Kamal E (2012) Primary Sjögren's syndrome and B-non-Hodgkin lymphoma: role of CD4+ T lymphocytopenia. Rheumatol Int 33:1021-1025
48. Kramer JM (2014) Early events in Sjögren's syndrome pathogenesis: the importance of innate immunity in disease initiation. Cytokine. doi:10.1016/j.cyto.2014.02.009
49. Weng MY, Huang YT, Liu MF, Lu TH (2012) Incidence of cancer in a nationwide population cohort of 7852 patients with primary Sjögreńs syndrome in Taiwan. Ann Rheum Dis 71:524-527